Full Breakdown
Johnson & Johnson Proposes $5.5 B Settlement to End U.S. Talc Litigation
7/28/2026, 8:40:57 AM
Core Event
On July 27, 2026, Johnson & Johnson announced an agreement in principle to resolve its remaining U.S. talc lawsuits by offering up to $5.5 billion. The proposal would cover tens of thousands of ovarian-cancer claims linked to the company’s former talc-based baby powder and other products. Finalization requires acceptance by 95 % of claimants in federal or state courts.
Background & Context
- 2009 – First ovarian-cancer lawsuit filed.
- 2016 – New Jersey jury ordered $72 million in damages; verdict overturned in 2017.
- 2020 – J&J stopped selling talc-based baby powder in the United States.
- 2022 – Worldwide discontinuation of talc-based baby powder.
- 2024 – WHO classified talc as “probably carcinogenic to humans.”
- 2025 – Litigation resumed after the company’s “Texas two-step” bankruptcy strategy was dismissed.
Timeline
- July 27, 2026 – Settlement announced; initial payment of up to $3 billion slated for 2027, with remaining amounts due by 2028.
- July 28, 2026 – Diyar Güldogan reports the agreement is contingent on 95 % claimant participation.
Data & Statistics
- Claims covered: J&J cited about 69,000 cases; Reuters reported approximately 76,000.
- Share of outstanding cases: The settlement would resolve 99.75 % of remaining U.S. talc claims.
- Payment schedule: Up to $3 billion in 2027; total exposure could exceed $7 billion if full participation occurs, according to plaintiff attorney Chris Seeger.
Official Statements & Responses
- Plaintiffs’ counsel called the deal a “good resolution” after a decade of court battles.
- The settlement does not address future talc claims and excludes the United Kingdom, where a separate case involving more than 7,000 claimants proceeds before the High Court.
Conflicting Reports & Gaps
- Number of claims: J&J’s “about 69,000” figure differs from Reuters’ “approximately 76,000.”
- Payout ceiling: The agreement caps qualifying ovarian-cancer claims but leaves the overall payout open, with estimates ranging from $5.5 billion to $7 billion or more, depending on participation.
- Future litigation: The settlement covers only existing claims; handling of any new lawsuits remains unclear.
Verbatim Quotes
- “While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” — Erik Haas
- “We got a fair settlement, and our ?clients are going to be happy with it,” — Chris Seeger
What’s Next
- The settlement becomes binding only after 95 % of claimants assent.
- An initial $3 billion payment is scheduled for 2027, with the balance due by 2028.
- Monitoring of the UK High Court case will determine whether additional liability arises outside the United States.
